Prevision Medicine, a Swiss-based company and leader in functional precision oncology, today announced the clinical launch of its AML Drug Screening Test for research use only, powered by the company’s proprietary PrevisionOne platform. The test is designed to help oncologists rapidly identify the most effective therapies for patients with acute myeloid leukemia (AML).

AML is one of the most aggressive and heterogeneous forms of blood cancer, and because of its rapid progression, treatment often needs to begin within just a few days. Prevision Medicine’s AML Drug Screening Test enables clinicians to make more informed, patient-specific treatment decisions by evaluating patient-derived malignant and non-malignantcells against more than 100 drugs and drug combinations, only requiring small samples of blood or bone marrow.